Xenikos B.V., a clinical-stage biopharmaceutical company currently developing a novel therapy for treating immune related disorders, announced today the closing of EUR 40M in convertible debt consisting of two equal tranches of EUR 20M. The financing was led by Veloxis Pharmaceuticals, Inc., with participation from existing investors, Medicxi, RA Capital Management, Oost NL and Sanquinnovate. In connection with the financing, Veloxis will obtain two sequential call options, each becoming active upon the release of its associated tranche, which provides Veloxis the exclusive option to exercise its right to acquire all of Xenikos’ outstanding shares.
Xenikos will use the proceeds of the financing to initiate a registrational Phase 3 clinical trial in the US and EU, which is designed to evaluate the efficacy and safety of their flagship product T-Guard® for the treatment of steroid-refractory acute graft-versus-host disease (SR-aGVHD) in patients following allogeneic stem cell transplantation versus ruxolitinib.
NautaDutilh's deal team consisted of Sybren de Beurs, Jeanine Evertse, Frans Ruijs (Corporate M&A), Florine Kuiperi (Corporate M&A notarial), Nina Kielman and Ash Beesemer (Tax).
Goodwin Procter LLP acted as US counsel to Xenikos.